Your session is about to expire
← Back to Search
Hormone Therapy
PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer (PROMOTE Trial)
N/A
Recruiting
Led By Hanny Pijnenborg, MD PhD
Research Sponsored by Radboud University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
No Placebo-Only Group
All Individual Drugs Already Approved
Approved for 10 Other Conditions
Summary
The PROMOTE study aims at optimising use of hormonal therapy in advanced stage and recurrent endometrial cancer analysing tumor tissue taken before start of hormonal therapy
Eligible Conditions
- Endometrial Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Clinical benefit rate
Progression free survival
Response rate
Secondary study objectives
Health-related quality of life
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.
Trial Design
1Treatment groups
Experimental Treatment
Group I: EC patients with HTExperimental Treatment1 Intervention
Patients with advanced stage or recurrent endometrial cancer treated with hormonal therapy
Find a Location
Who is running the clinical trial?
Radboud UniversityLead Sponsor
728 Previous Clinical Trials
298,405 Total Patients Enrolled
3 Trials studying Endometrial Cancer
78 Patients Enrolled for Endometrial Cancer
The Netherlands Cancer InstituteOTHER
302 Previous Clinical Trials
214,405 Total Patients Enrolled
1 Trials studying Endometrial Cancer
12 Patients Enrolled for Endometrial Cancer
Hospital del MarOTHER
89 Previous Clinical Trials
443,898 Total Patients Enrolled
Leiden University Medical CenterOTHER
558 Previous Clinical Trials
607,145 Total Patients Enrolled
5 Trials studying Endometrial Cancer
3,251 Patients Enrolled for Endometrial Cancer
Catharina Ziekenhuis EindhovenOTHER
150 Previous Clinical Trials
127,450 Total Patients Enrolled
Canisius-Wilhelmina HospitalOTHER
47 Previous Clinical Trials
31,685 Total Patients Enrolled
Royal Cornwall Hospitals TrustOTHER
26 Previous Clinical Trials
36,434 Total Patients Enrolled
3 Trials studying Endometrial Cancer
516 Patients Enrolled for Endometrial Cancer
Hospital Vall d'HebronOTHER
92 Previous Clinical Trials
69,464 Total Patients Enrolled
1 Trials studying Endometrial Cancer
103 Patients Enrolled for Endometrial Cancer
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER
706 Previous Clinical Trials
2,718,174 Total Patients Enrolled
1 Trials studying Endometrial Cancer
40 Patients Enrolled for Endometrial Cancer
Erasmus Medical CenterOTHER
710 Previous Clinical Trials
2,098,455 Total Patients Enrolled